The dynamics of the CAR-T cell therapy market for multiple myeloma are anticipated to change due to extensive R&D activities, increased investment in research and development of new CAR-T cell ...

Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...

The multiple myeloma CAR-T market is growing due to the strong clinical success of BCMS-targeted therapies and rising cases of relapsed or refractory patients, reports Towards Healthcare a sister firm ...

The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend ...

Phase 2 Trial in Multiple Myeloma Nears Key ReadoutPreparing for Expansion into Sickle Cell Disease and Acute Myeloid ...

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies ...

Collaboration between community practices and academic institutions is crucial for administering bispecific antibodies, with ...

Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development ...

"This is what I had to do. My mother gave me my grandmother's silver, and I cashed it in to pay for my medical bills," retired critical care nurse Janet Kerrigan told The Post.

Investor reaction to the deal was muted, with BMO Capital Markets analysts saying they "continue to look for more" from ...

Orbital is developing so-called in vivo CAR-T treatments, which are effective at treating certain blood cancers, but are ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...